Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Pharma Equity Group - Market Update & Q&A

By HC Andersen Capital
Pharma Equity Group

Meet and ask questions to CEO Thomas K. Selsø from Pharma Equity Group on Monday, December 11th, 2023 at 2 PM. CEO Thomas K. Selsø will provide an update on what has happened in 2023 and outline focus areas for 2024 which will be followed by a Q&A session. No question is too big or too small, everyone should have the opportunity to ask questions.

Pharma Equity Group focuses on repositioning existing APIs (Active Pharmaceutical Ingredients) for other indications. Pharma Equity Group acquired a larger portfolio of phase 2 projects through the purchase of Reponex, within major disease areas. These include bacterial peritonitis, chronic skin wounds, inflammatory bowel diseases, as well as colon and rectal cancer. The company operates with a partnership structure for all its phase 3 projects.

Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 20.11.2023, 2.45 PM.

Recent videos

Carasent, Audiocast, Q1'26
14.04.2026 klo 09.00 Carasent
Revenio’s press conference on the Visionix acquisition
13.04.2026 klo 14.00 Revenio Group
Duell, Webcast, Q2'26
09.04.2026 klo 10.30 Duell
Thule Group, Audiocast, Pre-silent 26
30.03.2026 klo 17.00 Thule Group
Puuilo Q4’25: Still the star in the sector
30.03.2026 klo 14.35 Puuilo
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.